Claritas Pharmaceuticals Inc V.CLAS.H

RE:RE:RE:RE:RE:Possible news release next week ?

[AngelaL]

No, that's not correct. Viral evolution is not always in the direction of more infectious and less deadly strains. Witness the flu epidemic in 1918 in which the virus evolved into a more deadly form and killed millions in a single year. Or the more recent instance where flu evolved into the H1N1 strain which was extraordinarily more deadly than the the strain from the year before. There are many factors at work simultaneously during viral evolution, so that the level of infectivity and deadliness (ie virulence) may rise or fall. In the case of COVID-19, the new strains in the UK, Brazil, and South Africa are in fact much far more infective and virulent, as evidenced over the past month in Manaus (Amazon), England (UK), and Capetown (South Africa). Vaccine makers are desperately trying to cope with these three new strains because the protectiveness of existing vaccines is markedly diminished against the new mutants in the RGB region (where these strains are all altered). By the time the new vaccines are ready (possibly Q1 2022) there will be dozens of new mutant strains (because of the high rate of mutation demonstrated to date for this virus) and some of these strains will likely have evolved to avoid the selective pressure of the new vaccines. Kalytera appears to be leading the way with a non-vaccine approach that will be able to address vaccine-resistant mutant strains. This is a bold company that is doing the right thing for all of us.